Acarbose in Combination with Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
The purpose of this study is to determine the safety and tolerability of acarbose in combination of immunotherapy based standard of care therapy in advanced renal cell carcinoma patients.
Kidney Cancer
DRUG: Acarbose Tablets
To assess the safety profile of acarbose in addition to standard of care (SOC) treatment in RCC, adverse events will be defined and assessed using the National Cancer Institute's Common Terminology Criteria (CTCAE) v5.0, 2 years|To assess the effect of acarbose on the gut microbiome in patients receiving as standard of care therapy., Fecal microbiota populations will be characterized prior, during and after treatment with acarbose., 2 years
To assess the efficacy of Acarbose in combination with SOC treatment in RCC, Estimate of the median progression free survival (mPFS) of patients treated with SOC + Acarbose, 2 years|To assess the efficacy of Acarbose in combination with SOC treatment in RCC, Estimate of the median overall survival (mOS) of patients treated with SOC + Acarbose, 2 years
The purpose of this study is to determine the safety and tolerability of acarbose in combination of immunotherapy based standard of care therapy in advanced renal cell carcinoma patients.